Skip to main content
PMHS
OTC Life Sciences

Polomar 10-Q: Q3 Revenue $1.13M, Restatement Adds $490K to Losses, Going Concern Doubt

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Healthcare
Sentiment info
Negative
Importance info
8
Price
$0.125
Mkt Cap
$3.549M
52W Low
$0.065
52W High
$840,000
52W Position info
92% above low
Off High info
100% below high
Rel. Volume info
0.3× avg
Market data snapshot near publication time

PMHS sits 92% above its 52-week low of $0.065 on light trading volume (0.3× avg).

Summary

Polomar grew Q3 revenue to $1.13M but lost $513,550, quantified a $490,433 restatement of its first-half 2026 results, and repeated substantial doubt about its ability to continue as a going concern.


Key Events · Earnings and Guidance · PMHS

  • Q3 Revenue Jumps to $1.13M

    Revenue rose to $1,133,775 for the three months ended September 30, 2026 from $6,163 a year earlier, driven by prescription fulfillment volume; nine-month revenue was $3,739,944.

  • Quarterly Loss of $513,550

    Net loss was $513,550 for Q3 2026 and $829,002 for the nine months, with gross margin at 45.4%.

  • Restatement Adds $490,433 to Losses

    Corrections increased net loss by $393,551 for Q1 2026 and $96,882 for Q2 2026, a total of $490,433 for the six months ended June 30, 2026; amended 10-Q/As are still to be filed.

  • Going Concern Doubt Reaffirmed

    Management cited $254,779 of cash and a $14,565,652 accumulated deficit as raising substantial doubt about the ability to continue as a going concern for one year.


Analysis · PMHS · Life Sciences

Polomar's first full quarter of commercial pharmacy operations generated $1,133,775 in revenue, up from $6,163 a year earlier, yet the company still lost $513,550 in the quarter and $829,002 over nine months. Hard numbers now attach to the restatement first flagged on November 3: correcting unrecorded commissions, expenses booked to inventory, mis-timed revenue and the preferred stock classification added $393,551 to the Q1 2026 net loss and $96,882 to Q2, $490,433 in total. Management also reaffirmed substantial doubt about continuing as a going concern — $254,779 of cash against a $14,565,652 accumulated deficit — and said the material weaknesses that caused the errors were not remediated as of September 30. The related-party Profesco note held by Interim CEO Tierney has been in default since January 1, 2026 and now accrues 18%.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 48.2% of the 1980 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, PMHS was trading at $0.13 on OTC in the Life Sciences sector, with a market capitalization of approximately $3.5M. The 52-week trading range was $0.07 to $840,000.00. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

PMHS - Latest Insights

PMHS
Nov 13, 2026, 5:21 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.12504
Real-time Price: $0.12504 info
Change: $0 (0%) info
Market Cap: $3.549M info
PMHS
Nov 03, 2026, 4:41 PM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.1875
Real-time Price: $0.12504 info
Change: -$0.06246 (-33%) info
Market Cap: $3.549M info
PMHS
Oct 19, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.120
Real-time Price: $0.12504 info
Change: +$0.00504 (+4%) info
Market Cap: $3.549M info
PMHS
Aug 14, 2026, 4:06 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.140
Real-time Price: $0.12504 info
Change: -$0.01496 (-11%) info
Market Cap: $3.549M info
PMHS
Jul 17, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.118
Real-time Price: $0.12504 info
Change: +$0.00704 (+6%) info
Market Cap: $3.549M info